Evidence map›Paper›PMID 29435107›Full record

ArticleOncotarget2018

Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia.

Apollinaire Ngankeu, Parvathi Ranganathan, Violaine Havelange, Deedra Nicolet, Stefano Volinia, Bayard L Powell, Jonathan E Kolitz, Geoffrey L Uy, Richard M Stone, Steven M Kornblau and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. MicroRNAs in Leukemias: A Clinically Annotated Compendium.International journal of molecular sciences · 2022
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. MicroRNA replacement therapy in cancer.Journal of cellular physiology · 2019
    Review
  11. MicroRNAs in Autoimmunity and Hematological Malignancies.International journal of molecular sciences · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 3 countries.

Apollinaire NgankeuDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Parvathi RanganathanDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Violaine HavelangeHematological Department, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Deedra NicoletComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Stefano VoliniaDepartment of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.
Bayard L PowellThe Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC, USA.
Jonathan E KolitzNorth Shore Cancer Institute, Lake Success, NY, USA.
Geoffrey L UySiteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Richard M StoneDana-Farber Cancer Institute, Harvard University, Boston, MA, USA.
Steven M KornblauDepartment of Leukemia, MD Anderson Cancer Center, Texas State University, Houston, TX, USA.
Michael AndreeffDepartment of Leukemia, MD Anderson Cancer Center, Texas State University, Houston, TX, USA.
Carlo M CroceDepartment of Molecular Virology, Immunology and Medical Genetics at The Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Clara D BloomfieldDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Ramiro GarzonDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
The Ohio State University · USThe University of Texas MD Anderson Cancer Center · USCliniques Universitaires Saint-Luc · BEDana-Farber Cancer Institute · USNorthwell Health · USUniversity of Ferrara · ITWake Forest University · USWashington University in St. Louis · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
THE THERAPY OF AMLP01CA055164 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI THOMAS, MATTIE J · 1992 to 2011
$25.3M
Washington University/ Siteman Cancer Center Lead Academic SiteU10CA180833 · NCI · WASHINGTON UNIVERSITY · PI BARTLETT, NANCY L, KOZOWER, BENJAMIN D · 2014 to 2018
$7.6M
Cancer Gene Discovery to Identify Targetable TargetsR35CA197706 · NCI · OHIO STATE UNIVERSITY · PI CROCE, CARLO M · 2015 to 2021
$6.4M
ITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" TherapieU10CA180861 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D, MARCUCCI, GUIDO · 2014 to 2018
$3.4M
NCI NIH HHS P01 CA055164NCI NIH HHS P30 CA016058NCI NIH HHS R35 CA197706NCI NIH HHS U10 CA180833NCI NIH HHS U10 CA180861
6 · The paper itself

Abstract

We previously reported that microRNA (miR)-29b is down-regulated and has a tumor suppressor role in acute myeloid leukemia (AML). However, little is known about the mechanisms responsible for miR-29b expression downregulation in AML. In this work we screened for mutations that could affect miR-29b expression. Using Sanger sequencing, we identified a germline thymidine (T) base deletion within the miR-29b-1/miR-29a cluster precursor in 16% of AML patients. Remarkably we found a significant enrichment for the presence of the miR-29 polymorphism in core binding factor (CBF) newly diagnosed AML patients (

Indexed as

AMLmiR-29b-1/miR-29a clusterpolymorphism

Identifiers

PMID29435107
PMCPMC5796978
OpenAlexW2772482622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.